26 August 2024 - Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.

BeiGene today announced that the US FDA has granted fast track designation to BGB-16673, an orally available investigational Bruton’s tyrosine kinase targeting chimeric degradation activation compound, for adult patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma who have been previously treated with at least two prior lines of therapy, including a Bruton’s tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor.

Read BeiGene press release